益生菌制剂可能是改善神经炎症相关疾病（例如阿尔茨海默氏病）的有希望的干预措施

益生菌配方预处理（Helveticus r0052和Bifidobacterium longum r0175）对脂多糖大鼠模型的影响。

j am coll Nutr。 2018年10月11日：1-9。 EPUB 2018年10月11日。PMID： 30307792 30307792 Peymani，Yazdan Mirzanejad，Safar Ali Alizadeh，Taghi Naserpour，Marjan Nassiri-Asl

Ghazaleh Mohammadi

方法： 大鼠被随机分为四组（对照，LPS，LPS，益生菌+LPS和益生菌）。所有实验组均连续14天口服麦芽糊精（安慰剂）或益生菌（10 CFU/mL/大鼠），然后在20个小时后注入盐水或LPS（1 mg/kg，腹膜内[I.P.]，单剂量，单剂量）。 Memory retention ability and systemic and neuroinflammatory markers were assessed 4 hours after the injections.

RESULTS: Systemic exposure to LPS resulted in significant elevation of both the circulating and hippocampal levels of proinflammatory cytokines, which decreased remarkably foll欠益生菌预处理。口服细菌疗法与Helveticus r0052和B. longum R0175结合使用，还减弱了通过分子水平通过脑衍生的神经营养因子（BDNF）表达LPS对记忆的降低作用。 however, this effect was not significant in the passive avoidance test at the behavioral level.

CONCLUSIONS: These results suggest that the management of gut microbiota with this probiotic formulation could be a promising intervention to improve neuroinflammation-associated disorders such as AD.